Correction: Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

Abstract

The publisher would like to report an error that appeared in a recently published article [1]. The y-axis label in Figure 3A has been corrected as of 13 September 2017 and should read 'Median increase in CD4 + T-cell counts, cells/mm 3 '. The accompanying footnote has also been amended and the correct version is shown. The authors apologize for this error.

Optimizing Antiretroviral Therapy in Treatment-Experienced Patients Living with HIV: A Critical Review of Switch and Simplification Strategies. An Opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy

“…Serious AEs and treatment discontinuations were low in both groups of an open label randomized study of participants switched to DTG/3TC/ABC from various baseline regimens at study entry (early-switch group) or at week 24 (late-switch group). 23 The most common AEs in the early-switch group were nausea (10%), fatigue (7%), diarrhea (6%), and headache (5%), which occurred in 1% of the late-switch participants during weeks 1 to 24. Psychiatric AEs were more common in the early-switch group compared to the late-switch group during weeks 1 to 24 and weeks 24 to 48 (13% versus 3% and 9%, respectively) and included mainly grade 1 and grade 2 effects.…”

“…Virologic suppression was evaluated in 4 studies that switched patients to a DTG-based regimen from baseline ART (Table 2). 23–25,31 Each study showed high level of virologic suppression after the switch, ranging from 92% to 97%.…”

No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.

“…In our study we observed no impact of previous NRTIs resistance according to the historical GRT on the risk of VF of ART composed by DTG+2 NRTIs. This finding is interesting because no information is available from randomized clinical trial due to the exclusion of patients with previous NRTIs mutations [6,7]. Nevertheless, a recent large observational study conducted in several European countries confirmed the absence of the impact of M184V/I on the virological efficacy of ABC/3TC/DTG regimen in switch strategy [15].…”

“…In the past decades antiretroviral therapy (ART) has dramatically changed the natural history of HIV-1 infection by transforming an invariably fatal disease into a chronic one [1]. The advent of a new class of antiretroviral, integrase inhibitors (INIs), has provided new effective and well tolerated ART options both in naïve [2][3][4][5] and experienced patients [6][7]. Simplification strategies based on INIs are increasingly used in clinical practice with the aim to improve the tolerability and to avoid potential long-term metabolic untoward effects of other antiretrovirals, i.e.…”

“…RAL and elvitegravir), dolutegravir (DTG) presents a higher genetic barrier [13]. Nevertheless, due to the high rate of VF observed in the SWITCHMRK, patients with previous VF, with documented resistance to one of the investigated ART components, were subsequently excluded from the DTG switch studies [6,7,11]. Therefore, only data derived from observational studies are available regarding the potential impact of previous reverse transcriptase (RT) mutations on the virological efficacy of DTG triple therapy [14 -16].…”